Publications
60
Citations
140
Est. group size
~28
Recurring co-author estimate
Active years
13
Publishing since 2014
Pannaga Malalur works in oncology, focusing on gastrointestinal cancers (including hepatocellular carcinoma, colorectal, and pancreatic cancers) and prostate cancer, with attention to treatment approaches like immune-checkpoint inhibitors, locoregional therapies, and liver-directed treatments. Additional work covers clinical care quality topics such as clinical documentation improvement, appropriate laboratory testing practices, and cancer survivorship. This research combines clinical trial reporting, real-world outcomes analysis, and health systems/quality improvement studies.
Publication output was modest and fluctuating from 2018-2023 (0-5 papers/year) but increased sharply in 2024-2025, suggesting a recent growth phase in research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Closing the documentation gap: CDI physician advisor education and its effect on quality metrics.
Journal of Clinical Oncology · 2026
- Abstract CT155: Phase 1b trial of NG-350A, a CD40 agonist antibody expressing adenoviral vector, in combination with chemoradiotherapy (CRT), in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC): Initial results from the FORTRESS study
Cancer Research · 2026
- The Combined Use of Lenvatinib and Locoregional Therapies for the Management of Hepatocellular Carcinoma
Cancers · 2025
- Real-world insights into immune-related adverse events (irAE) in gastrointestinal (GI) malignancies.
Journal of Clinical Oncology · 2025
- Improving expected mortality through CDI physician advisor engagement: Lessons from a comprehensive cancer center.
JCO Oncology Practice · 2025
- Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).
Journal of Clinical Oncology · 2024
- Predictors of poor response to immune-checkpoint inhibitor (ICI) treatment among patient with hepatocellular carcinoma (HCC).
Journal of Clinical Oncology · 2024
- Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration‐resistant prostate cancer
The Prostate · 2022
- Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis
Cancer Medicine · 2021
- Association of elevated serum CEA with visceral metastasis and distinctive circulating tumor DNA alterations in castrate-resistant prostate cancer.
Journal of Clinical Oncology · 2021
- Neurotoxic manifestations of high-dose intrathecal gadolinium administration for CT myelogram
Radiology Case Reports · 2020
- Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia
Journal of Thrombosis and Thrombolysis · 2019
- Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).
Journal of Clinical Oncology · 2019
- Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis.
Journal of Clinical Oncology · 2018
- Limited Impact of Clinician Education on Reducing Inappropriate PF4 Testing for Heparin-Induced Thrombocytopenia
Blood · 2018
- Journal of Clinical Oncology×29
- Journal of Thrombosis and Thrombolysis×2
- HPB×2
- Preprints.org×2
- Cancer Research×2
- Shafia Rahman
Medicine · The Ohio State University
- Arjun Mittra
Medicine · The Ohio State University
- Anita Turk
Medicine · Indiana University
- Patrick W. Underwood
Medicine · The Ohio State University
- Anne M. Noonan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile